Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Saved in:

Bibliographic Details
Main Authors:	Sho Iketani, Lihong Liu, Manoj S. Nair, Abishek Chandrashekar, Hiroshi Mohri, Maple Wang, Dan H. Barouch, Yaoxing Huang, David D. Ho
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Series:	Emerging Microbes and Infections
Online Access:	https://www.tandfonline.com/doi/10.1080/22221751.2021.2006581
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

Real-world effectiveness of Ad26.COV2.S or BNT162b2 booster vaccines against severe COVID-19 in adults who received a primary dose of Ad26.COV2.S in South Africa during the Delta period: A retrospective cohort study using medical scheme data
by: L Fairall, et al.
Published: (2025-08-01)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023-07-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines
by: David Hodgson, et al.
Published: (2025-03-01)

Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function.
by: Takayuki Yamaji, et al.
Published: (2024-01-01)

Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
by: Ho Yu Ng, et al.
Published: (2025-02-01)

Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
by: Aisling R. Caffrey, et al.
Published: (2024-11-01)

Immune Imprinting, Non-Durable Hybrid Immunity, and Hybrid Immune Damping Following SARS-CoV-2 Primary Vaccination with BNT162b2 and Boosting with mRNA-1273
by: Alejo Erice, et al.
Published: (2025-03-01)

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting
by: Aini Syahida Mat Yassim, et al.
Published: (2025-07-01)

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
by: Kayvon Modjarrad, et al.
Published: (2024-11-01)

Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
by: Claudio Ucciferri, et al.
Published: (2022-02-01)

Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
by: Anja Rosdahl, et al.
Published: (2024-12-01)

Elevated alanine transaminase in liver transplant recipients after BNT162b2 vaccination: a cohort study
by: Jacob Siewertsen Bergmann, et al.
Published: (2025-08-01)

Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine
by: Sydney Ann Kee, PhD, et al.
Published: (2025-08-01)

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
by: Younes Bathish, et al.
Published: (2024-12-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
by: Lilia M. Sierra Galan, et al.
Published: (2025-01-01)

BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
by: Chen-Wei Yen, et al.
Published: (2023-11-01)

Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System
by: Haley J. Appaneal, et al.
Published: (2025-04-01)

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data.
by: Lilac Tene, et al.
Published: (2023-01-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

Effect of recent SARS-CoV-2 infection on anti-spike protein immunoglobulin G II response after BNT162b2 vaccination
by: Daiki Tanno, et al.
Published: (2025-08-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024-12-01)

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
by: Frank van den Ouweland, et al.
Published: (2024-12-01)

Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer
by: K.L. Juliëtte Schmidt, et al.
Published: (2024-12-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
by: Masliyana Husin, et al.
Published: (2025-01-01)

Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty
by: Kuang-Jen Chien, et al.
Published: (2023-05-01)

Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescentsResearch in context
by: Qiong Wu, et al.
Published: (2025-01-01)

Allergy to PEG (polyethylene glycol) – sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024-12-01)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
by: Doris Urlaub, et al.
Published: (2021-12-01)

WCN24-1701 MINIMAL CHANGE DISEASE FOLLOWING THE SECOND DOSE OF PFIZER-BIONTECH (BNT162B1) FOR SARS-COV-2. COINCIDENCE OR CAUSALITY?
by: Juan Carlos González García, et al.
Published: (2024-04-01)

Relapse of Evans syndrome following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine: case report and literature review
by: Mirjana Cvetković, et al.
Published: (2023-06-01)

Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain
by: Luis Sarabia de Ardanaz, et al.
Published: (2025-05-01)

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
by: William N Whiteley, et al.
Published: (2022-02-01)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution
by: Andreina Baj, et al.
Published: (2021-01-01)

Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
by: Chandima Jeewandara, et al.
Published: (2022-01-01)